Sanofi-aventis and Regeneron Pharmaceuticals announced positive results from the Phase 3 VELOUR study of Zaltrap (aflibercept), also known as VEGF Trap, for the second-line treatment of metastatic colorectal cancer (mCRC). The VELOUR study was a multinational, randomized, double-blind trial comparing FOLFIRI chemotherapy regimen (leucovorin, 5-fluorouracil, and irinotecan) in combination with either Zaltrap or placebo in treating patients with mCRC after failure of an oxaliplatin-based regimen. The study enrolled 1,226 patients with mCRC who previously had been treated with an oxaliplatin-based regimen. The study met its primary endpoint of improving overall survival (OS) in the second-line treatment of mCRC.
Zaltrap is an angiogenesis inhibitor. This fusion protein binds all forms of vascular endothelial growth factor-A (VEGF-A), as well as VEGF-B and placental growth factor (PIGF), additional angiogenic growth factors that appear to play a role in tumor angiogenesis and inflammation. Zaltrap has been shown to bind VEGF-A, VEGF-B, and PlGF with higher affinity than their native receptors.